This is a non-core endpoint: only basic statistics are computed.
Benign neoplasm: Bladder
CD2_BENIGN_BLADDER_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleNone |
- |
2. Check conditionsNone |
|
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D30
- Name in latin
- Neoplasma benignum vesicae urinariae
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Bladder
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm: Bladder
- Benign neoplasm of urinary organs
- Benign neoplasm of urinary organs
- Benign neoplasms
- Benign neoplasms
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 322 | 113 | 209 |
| Unadjusted period prevalence (%) | 0.07 | 0.04 | 0.09 |
| Median age at first event (years) | 62.30 | 55.24 | 66.11 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 292
- Matched controls
- 2931
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D30.3
ICD-10 Finland
Benign neoplasm: Bladder
+∞
308.6
239
*
UKC02
NOMESCO Finland
Cystoscopy
27.6
131.0
223
302
KCD02
NOMESCO Finland
Transurethral resection of bladder
483.2
125.8
117
*
D41.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bladder
161.0
71.6
73
6
C67.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bladder
+∞
70.7
65
*
8120/3-C67.9
ICD-O-3
Transitional cell carcinoma, NOS, of bladder, NOS
+∞
53.8
50
*
R31
ICD-10 Finland
Unspecified haematuria
10.3
50.3
111
164
C67.9
ICD-10 Finland
Malignant neoplasm: Bladder, unspecified
567.1
49.9
48
*
KCD32
NOMESCO Finland
Cystoscopic destruction of tumour of bladder
105.8
42.1
45
5
C67.2
ICD-10 Finland
Malignant neoplasm: Lateral wall of bladder
+∞
40.6
38
*
2233A
ICD-9 Finland
Benign neoplasm of kidney and other urinary organs, Bladder
+∞
35.1
33
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
378.4
34.7
34
*
KCD05
NOMESCO Finland
Excision of bladder lesion during urinary tract endoscopy with photodynamic diagnosis (PDD)
131.8
33.5
35
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
31.8
30
*
UKC05
NOMESCO Finland
Cystoscopy and bladder biopsy
76.4
30.6
34
5
22330
ICD-8 Finland
Benign neoplasm of kidney and other urinary organs, Bladder
+∞
27.5
26
*
7323
FHL
Electrosection of TU bladder wall change
+∞
25.4
24
*
130
Kela drug reimbursment
Malignant tumour
+∞
25.4
24
*
D30.0
ICD-10 Finland
Benign neoplasm: Kidney
47.3
21.8
26
6
7321
FHL
TU biopsy, coagulation or laser
95.5
16.7
18
*
JN4BD
NOMESCO Finland
Extensive body CT
8.5
16.7
37
49
1530
FHL
Urethrocystoscopy
9.9
16.4
33
37
WX408
NOMESCO Finland
General anesthesy, balanced
3.3
15.8
93
358
116
Kela drug reimbursment
Prostate cancer
+∞
15.8
15
*
8120/1-C67.9
ICD-O-3
Urothelial papilloma, NOS, of bladder, NOS
+∞
14.7
14
*
J01MA02
ATC
ciprofloxacin; systemic
2.6
13.9
143
775
WX320
NOMESCO Finland
Spinalanesthesy
3.0
13.7
94
397
C67.0
ICD-10 Finland
Malignant neoplasm: Trigone of bladder
+∞
13.6
13
*
KCW02
NOMESCO Finland
Lavation of bladder for coagulated blood
29.9
13.1
17
6
C67.1
ICD-10 Finland
Malignant neoplasm: Dome of bladder
+∞
12.6
12
*
ZX136
NOMESCO Finland
Intravesicalis
48.7
12.0
14
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
11.5
11
*
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
+∞
11.5
11
*
KCB00
NOMESCO Finland
Biopsy of bladder
26.2
11.2
15
6
J01EA01
ATC
trimethoprim; systemic
2.8
11.1
86
384
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.1
10.8
64
241
8130/1-C67.9
ICD-O-3
Papillary urothelial neoplasm of low malignant potential of bladder, NOS
+∞
10.5
10
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
10.5
10
*
115
Kela drug reimbursment
Breast cancer
+∞
10.5
10
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
10.5
10
*
L02AE02
ATC
leuprorelin; implant, parenteral
56.9
9.7
11
*
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
56.9
9.7
11
*
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
4.5
9.6
34
83
8130/2-C67.9
ICD-O-3
Papillary urothelial carcinoma, non-invasive of bladder, NOS
103.1
9.5
10
*
R33
ICD-10 Finland
Retention of urine
3.4
9.4
46
150
18899
ICD-8 Finland
Malignant neoplasm of bladder
+∞
9.4
9
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
9.4
9
*
1888X
ICD-9 Finland
Malignant neoplasm of bladder, Other specified sites of bladder
+∞
9.4
9
*
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
7.7
9.4
21
29
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
3.0
9.2
57
220
WF002
NOMESCO Finland
Radical radiotherapy
51.5
8.7
10
*
KH1CD
NOMESCO Finland
Very extensive urinary tract ultrasound examination
16.9
8.6
13
8
XKD00
NOMESCO Finland
Uroflowmetry
2.6
8.4
69
314
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
8.4
8
*
C67.4
ICD-10 Finland
Malignant neoplasm: Posterior wall of bladder
+∞
8.4
8
*
L01BC06
ATC
capecitabine; oral
+∞
8.4
8
*
J01MA12
ATC
levofloxacin; systemic
2.5
8.2
72
340
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
10.5
8.1
15
15
A03FA01
ATC
metoclopramide; systemic, rectal
3.1
8.1
45
161
UJF32
NOMESCO Finland
Coloscopy
2.3
8.0
85
442
U06
ICPC
Haematuria
13.5
7.9
13
10
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.2
7.7
91
494
KH1BT
NOMESCO Finland
Urinary tract cathetrisation with X-ray guidance
25.7
7.6
10
*
TKC20
NOMESCO Finland
Catheterisation of bladder
3.4
7.5
36
116
WX402
NOMESCO Finland
General anaesthesia
3.1
7.5
42
151
Z08.0
ICD-10 Finland
Follow-up examination after surgery for malignant neoplasm
82.0
7.4
8
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
8.7
7.4
15
18
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
7.3
7
*
PJD54
NOMESCO Finland
Block dissection of iliac lymph nodes
+∞
7.3
7
*
C67
ICD-10 Finland
Malignant neoplasm of bladder
+∞
7.3
7
*
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
+∞
7.3
7
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
7.3
7
*
L02BB03
ATC
bicalutamide; oral
+∞
7.3
7
*
KCC10
NOMESCO Finland
Cystoprostatectomy
+∞
7.3
7
*
JN4AD
NOMESCO Finland
Body CT examination
5.2
7.1
21
43
A02BC02
ATC
pantoprazole; systemic
1.9
7.0
182
1341
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
2.3
6.9
71
360
N02BE01
ATC
paracetamol; systemic, rectal
2.2
6.7
241
1993
KCW96
NOMESCO Finland
Other operations on bladder
12.6
6.6
11
9
J01DB01
ATC
cefalexin; oral
2.0
6.5
223
1792
HAB40
NOMESCO Finland
Wedge excision of mammary gland
71.3
6.4
7
*
KH1BD
NOMESCO Finland
Extensive urinary tract CT examination
14.7
6.4
10
7
KBJ10
NOMESCO Finland
Cutaneous ureteroenterostomy
+∞
6.3
6
*
8090/3-C44.5
ICD-O-3
Basal cell carcinoma, NOS, of skin of trunk
+∞
6.3
6
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
6.3
6
*
C44.51
ICD-10 Finland
Basocellular carcinoma of the skin on the torso
+∞
6.3
6
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
6.3
6
*
D41.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Renal pelvis
+∞
6.3
6
*
B02AA02
ATC
tranexamic acid; systemic
2.9
6.3
37
139
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
27.3
6.3
8
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
27.3
6.3
8
*
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.0
6.1
34
122
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
160
858
2.72
17.22
6.5
3.0
—
—
—
0
0
217
1558
2.21
9.89
9.0
4.4
3327.2
2432.1
e6/l
—
6
30
36
117
3.33
9.24
3.1
1.4
3.9
5.1
ug/l
0.20
30
88
111
663
2.03
7.83
7.3
2.9
0.2
0.5
e6/l
3.78
90
489
64
308
2.34
7.79
2.7
2.4
18.3
23.6
%
3.28
55
267
164
1127
1.93
7.63
7.5
3.6
11.2
12.3
umol/l
1.20
158
1049
149
1002
1.90
7.32
4.9
3.5
—
—
—
0
0
77
411
2.15
7.27
6.5
2.6
1.5
1.1
e6/l
0.31
53
227
162
1123
1.89
7.21
5.5
3.8
0.0
0.0
estimate
0.00
30
173
66
332
2.24
7.21
2.6
2.3
2.3
2.3
g/l
0.31
61
304
166
1166
1.87
7.04
7.3
5.2
1.2
1.2
mmol/l
0.54
136
984
73
387
2.14
6.99
7.0
2.8
2.8
1.8
e6/l
0.29
49
204
107
654
1.95
6.93
2.3
2.1
2.6
3.1
mg/l
1.32
91
542
162
1140
1.85
6.73
5.6
3.8
0.0
0.0
estimate
0.00
30
165
169
1210
1.83
6.59
10.8
5.8
4.1
4.5
e9/l
0.92
149
1041
70
377
2.09
6.40
2.5
2.3
12.0
13.3
umol/l
0.54
64
343
159
1125
1.81
6.38
7.6
5.3
0.0
0.0
estimate
0.00
30
170
150
1063
1.77
5.83
5.6
4.8
1.2
1.2
mmol/l
0.28
136
937
33
141
2.49
5.17
1.8
1.4
—
—
—
0
0
137
974
1.71
5.08
3.2
2.6
146.5
137.9
ug/l
0.15
127
889
183
1417
1.67
4.83
5.4
4.0
6.9
6.8
mmol/l
0.09
174
1312
10
20
5.12
4.80
1.9
1.7
—
—
—
0
0
80
511
1.75
4.25
2.9
2.0
—
—
—
0
0
19
73
2.70
3.70
2.4
1.4
—
1.1
—
0
10
134
1011
1.56
3.60
6.6
3.5
34.2
35.2
g/l
1.41
126
935
64
412
1.69
3.26
2.2
1.7
—
—
—
0
0
104
755
1.56
3.25
4.0
2.0
2.4
2.3
mmol/l
0.16
86
608
48
285
1.80
3.24
1.9
1.7
—
—
—
0
0
117
875
1.53
3.19
6.1
4.0
—
—
—
0
0
12
39
3.15
3.11
1.4
1.2
—
—
—
0
0
7
12
5.93
3.03
2.9
1.4
13.2
11.9
ug/l
—
7
12
5
5
10.11
2.98
2.2
7.8
—
—
—
0
0
42
246
1.81
2.96
4.3
3.0
—
—
—
0
0
78
544
1.57
2.87
5.4
4.2
1.0
1.0
kg/l
0.55
18
98
98
720
1.52
2.85
3.2
2.1
50.6
57.3
u/l
1.51
93
663
79
554
1.56
2.84
1.7
1.8
1014.1
1204.2
nmol/l
1.25
59
417
29
153
1.98
2.80
2.4
1.7
—
—
—
0
0
46
285
1.71
2.69
2.0
1.7
—
—
—
0
0
47
294
1.70
2.66
7.2
5.3
105.2
104.1
mmol/l
0.96
47
288
18
80
2.32
2.65
2.8
3.7
—
—
—
0
0
28
149
1.96
2.64
1.3
1.5
—
—
—
0
0
59
395
1.60
2.57
31.8
28.5
1.4
1.4
inr
0.09
13
50
83
603
1.50
2.52
5.7
3.9
0.0
0.0
estimate
0.00
30
165
28
152
1.92
2.51
6.1
3.8
1.9
2.1
mmol/l
0.07
21
112
145
1175
1.42
2.49
2.7
2.6
—
—
—
0
0
45
286
1.66
2.41
5.4
5.5
0.5
1.3
mmol/l
0.84
36
221
13
52
2.56
2.38
1.4
1.7
—
—
—
0
0
34
201
1.77
2.35
4.9
5.0
1.5
1.5
mmol/l
0.03
34
191
257
2326
1.52
2.32
24.7
13.4
23.0
25.7
mg/l
0.72
224
1807
11
41
2.74
2.29
1.8
1.9
13.8
16.0
%
—
6
24
87
655
1.45
2.19
3.4
2.5
373.9
10657.9
umol/l
3.84
72
568
79
584
1.47
2.18
1.8
1.8
398.9
11975200.2
pmol/l
0.50
63
476
14
61
2.35
2.17
1.4
1.6
0.3
0.1
iu/ml
—
5
17
110
871
1.40
2.08
3.6
3.2
1858.6
1931.0
ng/l
0.07
93
747
5
10
5.05
2.07
2.4
2.1
—
—
—
0
0
19
100
1.95
1.89
2.4
1.6
—
—
—
0
0
266
2455
1.48
1.88
26.9
16.5
139.7
139.8
mmol/l
0.14
260
2368
199
1751
1.35
1.87
5.8
4.0
15.4
12.6
mm/h
1.27
188
1572
266
2459
1.47
1.83
27.1
16.6
4.0
4.0
mmol/l
0.20
259
2370
5
12
4.21
1.82
1.8
1.2
—
—
—
0
0
195
1714
1.35
1.82
4.5
3.4
14.9
14.9
pmol/l
0.10
172
1521
8
29
2.80
1.80
1.5
1.2
—
—
—
0
0
5
13
3.88
1.72
1.2
1.2
—
—
—
0
0
12
55
2.22
1.69
2.3
1.8
122.2
131.0
g/l
—
6
37
10
42
2.42
1.69
1.9
1.2
—
—
—
0
0
13
62
2.14
1.67
1.7
1.6
—
—
—
0
0
8
31
2.62
1.66
1.6
1.2
—
—
—
0
0
5
14
3.60
1.62
1.4
1.0
—
—
—
0
0
5
14
3.60
1.62
1.4
1.0
—
—
—
0
0
6
21
2.89
1.51
1.3
1.1
—
—
—
0
0
137
1169
1.30
1.48
6.0
4.0
2.3
2.1
ug/l
0.17
123
1034
160
1394
1.29
1.47
4.7
2.9
59.7
46.6
u/l
0.98
152
1276
130
1103
1.30
1.47
2.7
2.1
94.9
92.5
pmol/l
0.24
62
568
263
2454
1.39
1.46
27.6
15.9
87.7
84.1
umol/l
0.67
263
2454
6
22
2.75
1.44
1.3
1.1
—
—
—
0
0
6
22
2.75
1.44
1.3
1.1
—
—
—
0
0
124
1048
1.30
1.43
5.1
3.9
35.3
45.0
ng/l
0.72
94
782
104
859
1.31
1.43
4.7
4.0
10.0
10.0
mg/mmol
0.00
66
539
106
880
1.30
1.40
2.7
2.3
76.1
77.8
nmol/l
0.24
96
759
9
41
2.23
1.38
3.8
2.0
11.8
13.1
u/ml
—
9
32
6
23
2.63
1.37
1.2
1.1
—
—
—
0
0
6
23
2.63
1.37
1.3
1.1
—
—
—
0
0
6
23
2.63
1.37
1.3
1.1
—
—
—
0
0
5
17
2.97
1.36
2.2
1.2
—
—
—
0
0
6
134
0.44
1.31
1.2
1.8
—
—
—
0
0
6
24
2.52
1.30
1.3
1.3
65.3
52.3
pmol/l
—
6
24
8
34
2.38
1.30
3.4
1.2
—
—
—
0
0
11
55
2.03
1.28
1.3
1.3
—
—
—
0
0
9
44
2.07
1.27
1.1
1.4
—
—
—
0
0
35
247
1.47
1.25
5.2
3.4
1.4
1.9
mmol/l
0.40
30
198
19
116
1.68
1.24
6.9
6.9
23.7
24.7
mmol/l
0.93
19
104
8
37
2.19
1.22
1.6
1.4
—
—
—
0
0
8
37
2.19
1.22
1.6
1.2
—
—
—
0
0
5
19
2.65
1.22
2.2
1.4
—
—
—
0
0
231
2136
1.28
1.21
5.7
4.3
2.1
2.0
mu/l
0.24
210
1895
6
26
2.33
1.19
1.0
1.5
—
—
—
0
0
6
26
2.33
1.19
3.7
1.5
—
—
—
0
0
18
110
1.67
1.17
2.4
1.7
—
—
—
0
0
30
209
1.48
1.15
2.5
1.6
378.8
364.9
nmol/l
0.13
25
188
11
58
1.93
1.13
1.1
1.2
—
—
—
0
0
56
438
1.33
1.12
1.3
1.2
0.6
1.9
u/ml
1.44
12
113
27
185
1.50
1.12
4.0
2.1
54.0
61.4
ml/min/173m2
—
8
80
7
31
2.28
1.11
1.3
1.2
—
—
—
0
0
8
41
1.97
1.09
1.0
1.5
—
—
—
0
0
7
32
2.21
1.08
1.3
1.1
—
—
—
0
0
66
534
1.29
1.05
5.5
3.9
237.4
352.7
ng/l
0.27
58
442
5
23
2.19
0.98
2.2
1.1
—
—
—
0
0
5
23
2.19
0.98
1.0
1.0
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
12
69
1.77
0.97
2.9
2.3
0.3
0.3
u/ml
—
6
38
80
673
1.25
0.93
2.0
1.6
21.3
20.3
nmol/l
0.22
67
565
6
28
2.16
0.92
1.7
1.1
—
—
—
0
0
16
102
1.60
0.92
1.9
1.3
—
—
—
0
0
61
498
1.28
0.91
1.7
1.7
0.9
1.1
mg/l
1.10
47
385
6
30
2.02
0.87
2.0
1.3
—
—
—
0
0
18
120
1.53
0.87
4.8
3.7
23.8
24.1
mmol/l
0.14
18
107
8
44
1.84
0.86
1.9
1.3
—
—
—
0
0
230
2163
1.22
0.84
23.4
12.3
72.9
74.6
ml/min/173m2
0.55
201
1746
235
2217
1.22
0.82
7.5
6.6
41.8
40.8
mmol/mol
0.82
219
2035
10
58
1.74
0.80
1.2
1.7
—
—
—
0
0
0
24
0.00
0.79
0.0
1.1
—
—
—
0
0
0
24
0.00
0.79
0.0
1.1
—
—
—
0
0
0
24
0.00
0.79
0.0
1.1
—
—
—
0
0
0
24
0.00
0.79
0.0
1.1
—
—
—
0
0
0
24
0.00
0.79
0.0
1.1
—
—
—
0
0
9
53
1.72
0.76
1.8
1.2
—
—
—
0
0
11
67
1.66
0.75
2.3
1.2
0.0
0.0
g/l
0.00
11
60
42
336
1.29
0.75
4.8
5.0
32.3
32.5
%
0.04
27
217
5
26
1.93
0.71
1.0
1.1
—
—
—
0
0
35
278
1.29
0.66
1.4
1.5
—
—
—
0
0
5
28
1.79
0.66
1.2
1.0
—
—
—
0
0
11
70
1.59
0.65
2.3
1.2
0.0
0.0
g/l
0.00
11
61
256
2455
1.20
0.64
14.5
9.0
25.2
25.0
u/l
0.07
247
2325
5
29
1.73
0.64
1.2
1.5
253.8
342.2
pmol/l
—
5
23
20
147
1.38
0.63
1.5
2.0
—
—
—
0
0
14
99
1.43
0.54
1.0
1.0
—
—
—
0
0
231
2210
1.16
0.53
4.5
4.3
1.4
1.3
mmol/l
1.70
206
1985
41
344
1.22
0.51
1.4
1.3
40.5
14.5
u/ml
0.48
17
116
11
75
1.48
0.51
2.3
1.2
0.0
0.0
g/l
0.00
11
66
42
356
1.20
0.48
1.2
1.3
22.2
39.4
iu/ml
1.29
15
120
32
266
1.22
0.45
2.4
2.7
4.6
7.9
ug/l
1.06
24
225
12
87
1.39
0.42
3.8
4.2
4.0
3.9
mmol/l
0.14
12
82
5
33
1.52
0.41
1.0
1.1
—
—
—
0
0
0
17
0.00
0.40
0.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
17
133
1.29
0.39
2.2
2.5
1.5
1.2
%
0.41
17
133
11
80
1.39
0.38
2.4
1.2
38.5
36.9
g/l
0.41
11
63
6
43
1.40
0.35
1.5
1.4
—
—
—
0
0
209
2014
1.10
0.34
26.0
14.6
38.8
39.1
%
0.14
131
1298
6
46
1.31
0.33
2.2
1.3
—
—
—
0
0
11
84
1.32
0.30
2.3
1.2
0.1
0.3
g/l
0.43
11
71
66
606
1.11
0.28
1.8
1.7
1.4
1.3
mmol/l
0.29
59
500
237
2310
1.09
0.26
5.1
4.8
4.4
4.4
mmol/l
0.55
213
2098
236
2305
1.08
0.23
5.7
4.9
6.3
6.1
mmol/l
1.59
215
2066
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
2.3
—
13.8
—
0
12
234
2289
1.08
0.21
5.1
4.8
1.4
1.4
mmol/l
1.94
209
2073
6
50
1.20
0.20
1.2
1.3
—
—
—
0
0
6
50
1.20
0.20
1.2
1.3
—
—
—
0
0
36
328
1.11
0.19
11.0
7.4
—
—
—
0
0
19
216
0.87
0.18
1.6
1.3
—
—
—
0
0
7
58
1.21
0.18
1.9
1.9
—
—
—
0
0
8
70
1.14
0.16
1.6
1.3
—
—
—
0
0
97
929
1.06
0.16
5.5
3.9
20.3
24.8
%
3.02
51
463
241
2371
1.06
0.14
5.5
5.4
2.5
2.6
mmol/l
0.30
216
2149
8
100
0.79
0.14
1.1
1.3
—
—
—
0
0
50
472
1.07
0.13
4.5
2.1
2.5
2.4
mmol/l
1.97
42
393
15
133
1.13
0.12
1.7
1.8
—
—
—
0
0
5
48
1.04
0.09
1.4
1.8
—
—
—
0
0
66
638
1.04
0.08
4.1
2.8
0.8
0.8
ug/l
0.10
50
458
7
66
1.06
0.08
1.0
1.2
—
—
—
0
0
7
66
1.06
0.08
1.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
1.9
—
0
9
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
3.5
—
—
—
0
0
0
8
0.00
0.00
0.0
3.5
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
5.6
—
136.0
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.9
—
15.8
—
0
8
0
5
0.00
0.00
0.0
2.8
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
6
0.00
0.00
0.0
5.5
—
96.7
—
0
6
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.6
—
1.3
—
0
5
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_BLADDER_EXALLC – Benign neoplasm: Bladder
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).